The Asian Institute of Technology (AIT) in Thailand has signed a long term partnership agreement with Bilcare Limited involving multiple aspects of nanotechnology cooperation, higher education and adaptation of the path-breaking innovation - nonClonableIDTM Technology for effective use in sustainable development of the region.
Pune/ Bangkok, September 2, 2014: The Asian Institute of Technology (AIT) along with its Center of Excellence in Nanotechnology (COEN@AIT) signed a long-term agreement with Bilcare Ltd. to initiate new programs that are beneficial to both parties in a number of areas. In particular, the Memorandum of Agreement (MoU) represents the first step in the development of a unique academia-industry relationship— a model in which opportunities for technology adaptation and product development are in line with AIT’s education, training, research and regional sustainability programs. Specifically, advanced technologies like Bilcare’s nonClonableID™ (or nCiD™) technology are intended to create synergies that enable all stated objectives. This move represents Bilcare’s first agreement with an academic institution.
Bilcare’s non-clonable identification technology was prompted by serious concerns about the drug counterfeiting industry in the region as well as globally. Fake drugs pose serious threats to health. More generally, the growing menace of a wide range of fake consumables and products also causes serious problems for manufacturers, retailers and consumers that result in lost revenues, lost taxation and of course, potential health hazards— none of which contribute in a positive way to economic viability, social development and sustainability in the region.
The nonClonableID™ exploits, in an innovative way, the intrinsic nature of composite nanoscale and microscale particulates that, when embedded onto a specialty chip substrate, yields a technology-read system that is impossible to copy— even by the inventors of the technology. During the MoU signing ceremony, Bilcare's Executive Director and Chief Scientific Officer Dr. Praful Naik said that “the nonClonableID™ technology offers real-time, ‘anywhere-anytime’ identification, authentication and product tracking and tracing, making it by far the only effective technology that is capable of providing all three components in one integrated workable system. Anti-counterfeiting, electronic-pedigree and secured tamper proof packaging are also applications involved with the technology”.
AIT President Professor Worsak Kanok-Nukulchai stated that, in addition to the MoU signing being an ‘historic’ occasion due to the novelty of the proposed academic-industry relationship, “the MoU with Bilcare earmarks the launch of a unique collaborative initiative, the ‘way forward’, between academia and industry that enables the amalgamation of domain expertise leading to localization and adaptation of state-of-the-art technologies like ‘nonClonableID™ for accomplishing the shared vision of sustainable development of the region”. The Center of Excellence in Nanotechnology will establish a technical interface program for technology evaluation, validation, testing, local adaptation and training.
Bilcare Ltd., a global leader in offering packaging solutions for the pharmaceutical industry, has sales in over one hundred countries and operates multiple R&D and manufacturing centers in Europe, the United States and Asia.
About AIT:
The Asian Institute of Technology (AIT) is an international post-graduate institute founded in 1959 and is Asia’s pioneering institute established to help meet the region’s growing need for advanced learning in the fields of engineering, science, technology and management, research and capacity building. AIT’s mission is to develop highly qualified and committed professionals that play a leading role in the sustainable development of the region and its integration into the global economy. AIT is based in Thailand and has affiliated centers and alumni in over 80 countries around the world.
http://www.bilcare.com/media/press_releases_AIT-inks-partnership-with-Bilcare.htm
No comments:
Post a Comment